Ultrasensitive RNA in situ hybridization for detection of restricted clonal expression of low-abundance immunoglobulin light chain mRNA in B-cell lymphoproliferative disorders.

超灵敏RNA原位杂交用于检测B细胞淋巴增殖性疾病中低丰度免疫球蛋白轻链mRNA限制性克隆性表达。

Tubbs RR,Wang H,Wang Z,Minca EC,Portier BP,Gruver AM,Lanigan C,Luo Y,Cook JR,Ma XJ

阅读：611 American Journal of Clinical Pathology； 2013 November; 140 (5)

Abstract

To assess the feasibility of using a novel ultrasensitive bright-field in situ hybridization approach (BRISH) to evaluate κ and λ immunoglobulin messenger RNA (mRNA) expression in situ in B-cell non-Hodgkin lymphoma (NHL).
A series of 110 semiconsecutive clinical cases evaluated for lymphoma with historic flow cytometric (FCM) results were assessed with BRISH.
BRISH light chain restriction (LCR) results were concordant with FCM in 108 (99%) of 109 evaluable cases. Additional small B-cell lymphoma cohorts were successfully evaluated.
BRISH analysis of κ and λ immunoglobulin mRNA expression is a sensitive tool for establishing LCR in B-cell NHL when FCM results are not available.

摘要

评估使用新的超敏亮视野原位杂交法（BRISH）检测B细胞非霍奇金淋巴瘤（NHL）中κ和λ免疫球蛋白信使RNA（mRNA）表达的可行性。
对一组有传统流式细胞仪（FCM）检测结果的110例淋巴瘤临床病例进行了BRISH评估。
在109例可评价的病例中，有108例（99％）BRISH检测轻链限制性（LCR）的结果与流式细胞仪一致，并成功评估了另外的小B细胞淋巴瘤病例组。
在FCM结果不可靠时，κ和λ免疫球蛋白基因表达的BRISH分析是一种敏感的检测B细胞非霍奇金淋巴瘤LCR的方法。

full text

我要评论

共0条评论

本文译者

小谷
译文：51 篇